Clinical trial
Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects With a Recent Acute Coronary Syndrome
NCT00831441 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects With a Recent Acute Coronary Syndrome
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- March 31, 2009
- Completion date
- March 31, 2011
- Enrollment
- 7,484 (actual)
- Sites
- 1,012
Conditions
As the registry lists them; a condition with its own page is linked.